Study on relationship between levels of IL-1βin follicular fluid and IVF-ET outcome in PCOS patients

HUANG Ying; QIU Ying; TAN Xiu-qun

doi:10.3969/j.issn.1674-3806.2013.08.05

Abstract： Objective To investigate the effect of GnRH antagonist in IVF-ET on IL-1βin follicular fluid and the relationship between GnRH antagonist and IVF-ET outcome in polycystic ovarian syndrome ( PCOS) patients. Methods Seventy-six cases of PCOS patients undergoing IVF-ET between August 2011 and September 2012 were di-vided randomly into two groups:Group A(study group):28 patients with PCOS were subjected to a protocol of gona-dotropin-releasing hormone antagonist .Group B( control group ):48 patients with PCOS were subjected to a long pro-tocol of gonadotropin-releasing hormone agonist .The level of IL-βof the two groups and the relationships between Gn-RH antagonist and IVF-ET outcome were analyzed .Results The two groups were similar with respect to IL-1βin follicular fluid(P>0.05);the two groups were similar with respect to endometrium thickness , the number of oocyte, the mature rate of the oocytes , fertilization rates , cleavage rates , the rate of the high-quality embryos , implantation rate, pregnancy rate(P>0.05).The doses of gonadotropin and the days of administration in Group A was less than those in Group B(P<0.01).The levels of serum E2 on day of HCG administration, and the cycle cancellation rate in Group A was lower than that in Group B ( P<0.05 or 0.01 ) .The difference of the incidence rate of OHSS was not significant ( P>0.05 ) between the two groups .Conclusion It is demonstrated that GnRH antagonist in PCOS pa-tients undergoing IVF-ET did not alter levels of IL-1βin follicular fluid , the development of follicle and the oocyte competence .These results demonstrated the high-performance and safety of this drug on controlled ovarian stimulation protocol.